Prophylactic Drain Versus No Drain in Curative Gastric Cancer Surgery-A Randomized Controlled Trial

J Gastrointest Surg. 2022 Dec;26(12):2470-2476. doi: 10.1007/s11605-022-05480-0. Epub 2022 Oct 24.

Abstract

Background: The adoption of enhanced recovery after surgery protocols has questioned the placement of prophylactic drain after curative gastrectomy. A 2015 Cochrane meta-analysis did not find convincing evidence of routine drain placement in gastrectomy, but the quality of evidence was questioned. The present study compared short-term outcomes of prophylactic drain placement versus no drain in gastrectomy.

Methodology: The study is a prospective, non-inferiority, and randomized controlled trial. Histologically proven adenocarcinoma of the stomach undergoing curative gastrectomy with D2 lymphadenectomy was included in the study. Randomization was done intra-operatively. The primary outcome was a postoperative hospital stay. Secondary outcomes included the return of bowel function, achieving adequate enteral feeding, re-surgery, morbidity, and mortality.

Results: One hundred fifty-seven patients were registered, of which 108 patients underwent curative surgery, and were randomized to 54 patients in each group. The median age was 55 years (range: 23-78) and 58.5 years (range: 35-80) in the drain and no drain group. No significant difference was noticed in primary or secondary outcomes in both groups.

Conclusion: Avoid placing a prophylactic drain is not inferior to drain placement following gastrectomy with D2 lymphadenectomy for stomach adenocarcinoma. So, routine prophylactic drain placement can be avoided.

Keywords: Drain; Gastrectomy; Gastric cancer; Hospital stay; Morbidity.

Publication types

  • Meta-Analysis

MeSH terms

  • Adenocarcinoma* / pathology
  • Adenocarcinoma* / surgery
  • Gastrectomy / methods
  • Humans
  • Lymph Node Excision / methods
  • Middle Aged
  • Postoperative Complications / etiology
  • Postoperative Complications / prevention & control
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Stomach Neoplasms* / pathology